Commercial Strategies
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
![](/-/media/editorial/medtech-insight/2024/03/mti2403_medtechwomen_shepherd_maria_1200.jpg?rev=71bb37e160924452b8436d41e049f3a6&w=350&hash=C58AD91885D700E057C6C7F006C73BFA)
‘Why Am I Not Seeing More Women In The Hiring Mix?’ MedExec Women Founder Says It’s Time For Change
Maria Shepherd, co-founder of MedExec Women, a nonprofit that seeks to empower executive leaders in medtech, is preparing to host the group’s fifth annual conference in Boston, which is expected to draw 200 attendees. Shepherd spent more than two decades in the medical device industry before starting consulting firm Medi-Vantage. She talks to Medtech Insight about her own career path, how the industry is changing, and the importance of “grooming” the next generation of young medtech leaders.
![](/-/media/editorial/stock-images/business/business-growth-concept_1089895325_1200.jpg?rev=6b685d50841641e29c4d0825f2dc01ee&w=350&hash=2BC40DB9FEC4578ECC6CEEC37BECD2A2)
Alys Is An Asset Play Wanting Big Pharma Attention
Leaders of a new dermatology-focused biotech, which has launched with 14 development programs in its pipeline, explain the rationale behind the company creation and the ideal exit scenario.
![](/-/media/editorial/in-vivo/2024/02/iv2402_unravelingjpm24_1200-1.jpg?rev=0ed88d2755784a84b7dff56bc8d1760a&w=350&hash=A75A82F60632F509D59F3EA17C103AA2)
Unraveling #JPM24: Insights From Citeline Reporters And Analysts
As it often does, this year's J.P. Morgan Healthcare Conference could set the tone for the rest of the year in biopharma. In Vivo revisits the key questions coming out of the 2024 event.
![](/-/media/editorial/medtech-insight/00_regular-column-images/digitalhealth_roundup_1200.jpg?rev=a3b924ac74fd4f05bfde9e19f9c66ea6&w=350&hash=6F97547DA91630A66164D33237DA1370)
Digital Health Roundup: CES Biggest Hits; Apple Versus Masimo; Insulet Recalls Diabetes App
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with industry leaders in medtech and healthtech and demos of some of the most innovative tech seen at CES 2024 in Las Vegas. Hannah Daniel dives into the latest developments in the intellectual property dispute between Apple and Masimo over blood oxygen sensors in the newer Apple Watch models.
![](/-/media/editorial/in-vivo/2023/12/iv122023_plf_bio-europe-2023.jpg?rev=6d11df5318b1449f9c189468b8e18ea3&w=350&hash=BF5C0CC7F6BA90398BFD5710B5A5DA82)
Effective Integration Is The Key To BD Success For Ipsen
At the 2023 BIO-Europe conference, In Vivo sat down with Ipsen’s EVP and chief business officer, Philippe Lopes-Fernandes, to discuss the company’s business development strategy and future goals.
![](/-/media/editorial/in-vivo/2023/12/iv122023_arrows_shutterstock_1996465979.jpg?rev=d8d08efb97764643a1b53dc224987848&w=350&hash=568F3472386AC282405B8C9A1462B78F)
Outlook 2024: Shaping A Medtech Environment Where Technology Leads The Way
Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.
![](/-/media/editorial/in-vivo/2023/12/iv2311_covid_trends_1681289425_1200.png?rev=cc8b402844814f9cb27e61e498305fb4&w=350&hash=8F3F72E96E1ECD7A26815ADB72CCFC3B)
Industry Leaderboard Gains And Dips Were Still Marked By COVID-19
Pfizer held the number one spot on the Scrip 100 on the strength of its COVID-19 products, while some others faced challenging financial comparisons in 2022 because of COVID-19 headwinds.
![](/-/media/editorial/in-vivo/2023/12/iv122023_whisper_shutterstock_1398166880.jpg?rev=816fb8aa87bf42758476792ca752cb0e&w=350&hash=4FBB31FBCC7A8CED56BEF4AE4C98C76E)
Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.
![](/-/media/editorial/stock-images/geographical/europeglobe_dencg_478321069_1200x675.jpg?rev=3ddefe108283478fbe138ebfa7f9faa4&w=350&hash=100510E81234D6B652ADB159EEC85606)
Europe’s Biotech Sector Still In Reasonable Shape
Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.
![](/-/media/editorial/in-vivo/2023/11/iv112023_drug-pricing_shutterstock_520981504.jpg?rev=b06e15f8625146e99e733a332f51f5b5&w=350&hash=395D0507CDB5B5C773F1858174C3D2B8)
Industry CEOs Talk Drug Pricing, Value And The IRA
Value-based pricing for drugs remains largely a pipe dream in the US, industry leaders say, even as drug pricing pressure mounts.
![](/-/media/editorial/stock-images/abstract/sc2310_diversity_1808618392_1200.jpg?rev=69983d5b17634bf7b7ffab0541c91f05&w=350&hash=D4778207C017410B713DB2CF23903453)
Global Pharma Companies Must Nurture ‘Intercultural Intelligence’
Equality, Diversity and Inclusion (ED&I) carries huge potential for business and society. However, various events around the globe, including the Black Lives Matter movement, highlighted that there are unaddressed challenges which need to be tackled. PTC Therapeutics, a global biopharmaceutical company with presence in in Europe, Middle East and Africa (EMEA) has initiated a new ED&I program to further strengthen its values and encourage positive progress globally.
![](/-/media/editorial/medtech-insight/2023/09/mti2309_lsxboston_2_1200.jpg?rev=7429ef2e9dbe4cf9a28c5e6638d4b68f&w=350&hash=82E7E1798A815F0C06818CB10FC12C45)
‘Build A Company To Be Bought, Not Sold,' 'Match The Asset To The Capital,' And Other Advice From VC Experts
At the recent LSX World Congress USA in Boston, Medtech Insight’s Reed Miller moderated a panel of experienced medtech investors to discuss the current medtech venture financing environment and offer advice for entrepreneurs raising money to support their innovations.
![](/-/media/editorial/in-vivo/2023/08/iv092023_lightbulb_shutterstock_222867214.jpg?rev=6d426384f9bf4885b8cc951823eff1f0&w=350&hash=EF8E84B6D9380472E3DA7E75CD9530D9)
A Next-Gen Approach To Health Care Risk And Compliance
Across the health care industry, the increasing numbers of ethics violations, data breaches and reputational challenges reflect the growing magnitude and prevalence of compliance failures.
![](/-/media/editorial/hbw-insight/hbw-stock-images/eng_womanenergy_1130130428_1200.jpg?rev=d2c4caa65a954be0aead80782dfcdc91&w=350&hash=940AB3C30E2215DDCF8D7D197264A7FF)
Spinning Around – One Company's Bid To Diagnostic-ify The Metabolism
Lifespin is working on tools to characterize a patient’s metabolism and provide more detailed information about a disease.
![](/-/media/editorial/medtech-insight/2023/09/mt2309-bigfoot-shutterstock_2273378937.jpg?rev=a48949bbf72e4fa083f780b90175842e&w=350&hash=C8D1FCD02277F621CFB246EF10CAECF4)
Abbott Buys Bigfoot Biomedical – But What Lurks In The Forest?
Abbott and Bigfoot Biomedical have worked as partners for more than half a decade but will now continue as one. Analysts are questioning whether the merger will simply be a tuck-in for Abbott, or enable it to release an insulin pump of their own.
![](/-/media/editorial/in-vivo/2023/08/iv092023_questions-grow_shutterstock_1101838934.jpg?rev=d53e22d8b991477e9c294083cd5d1701&w=350&hash=09C269490BAA1C89AB1AB8FFD8AC65F5)
After All The Layoffs, Is Biopharma’s Headcount Still Growing?
While biotech layoffs and big pharma restructuring dominate the news in 2023, the sector’s job market remains buoyant.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.